Human Transmembrane Glycoprotein NMB ELISA Kit

This Human Transmembrane Glycoprotein NMB ELISA Kit from Innovative Research is intended for quantitative detection of human GPNMB in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). Strip well format. Reagents for up to 96 tests.

This human GPNMB ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for GPNMB has been precoated onto 96-well plates. Standards(NSO, A22-P486) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for GPNMB is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human GPNMB amount of sample captured in plate.

• Detection Target: Transmembrane Glycoprotein NMB
• Uniprot ID: Q14956)
• Reactivity: Human
• Cross-Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Range: 156pg/ml-10000pg/ml
• Sensitivity: <10pg/ml
• Storage Conditions: Store at 4?C for 6 months, at -20?C for 12 months. Avoid multiple freeze-thaw cycles. (Shipped with wet ice)

Additional Information: The capture antibody is a monoclonal antibody from mouse, the detection antibody is a biotinylated polyclonal antibody from goat. Expression system for standard: Transmembrane glycoprotein NMB is a protein that in humans is encoded by the GPNMB gene. In osteoblast progenitor cells, GPNMB works as a positive regulator of osteoblast differentiation during later stages of matrix maturation and mineralization that is mediated at least in part by BMP-2 in a SMAD1 dependent manner to promote osteoblast differentiation. GPNMB can enhance the repairing process in bone fracture, demonstrated by its high expression during chondrogenesis(soft callus) and osteogenesis(hard callus) compared to the intact femurs that is why Osteoactivin(OA) could be a novel therapeutic agent used to treat generalized osteoporosis or localized osteopenia during fracture repair by stimulating bone growth and regeneration. Similarly, GPNMB expression increases during osteoclast differentiation and it is functionally implicated in this process, possibly by promoting the fusion of osteoclast progenitor cells.; Immunogen sequence: 369